These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6403788)

  • 1. In vivo dopamine receptor binding studies with a non-radioactively labeled agonist, dipropyl-5,6-ADTN.
    Feenstra MG; Rollema H; Mulder TB; Westerink BH; Horn AS
    Life Sci; 1983 Mar; 32(12):1313-23. PubMed ID: 6403788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.
    Rollema H; Feenstra MG; Grol CJ; Lewis MH; Staples L; Mailman RB
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Apr; 332(4):338-45. PubMed ID: 3736679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo displacement by 3-PPP enantiomers of N,N-dipropyl-5,6-ADTN from dopamine receptor-binding sites in rat striatum.
    Carlsson A; Löfberg L
    J Neural Transm; 1985; 64(3-4):173-85. PubMed ID: 4086990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo dopamine receptor agonist binding in rat brain: relation with pharmacological effects.
    Feenstra MG; Rollema H; Mulder TB; De Vries JB; Horn AS
    Eur J Pharmacol; 1983 Jun; 90(4):433-6. PubMed ID: 6684056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo binding of N-n-propylnorapomorphine in the rat brain: regional localization, quantification in striatum and lack of correlation with dopamine metabolism.
    van der Werf JF; Sebens JB; Vaalburg W; Korf J
    Eur J Pharmacol; 1983 Feb; 87(2-3):259-70. PubMed ID: 6404643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN.
    Rollema H; Westerink BH; Mulder TB; Dijkstra D; Feenstra MG; Horn AS
    Eur J Pharmacol; 1980 Jun; 64(4):313-23. PubMed ID: 7389825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar binding of 3H-ADTN and 3H-apomorphine to calf brain dopamine receptors.
    Seeman P; Woodruff GN; Poat JA
    Eur J Pharmacol; 1979 Apr; 55(2):137-42. PubMed ID: 456412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal binding of 2-amino-6,7-[3H]dihydroxy-1,2,3,4-tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics.
    List SJ; Wreggett KA; Seeman P
    J Neurosci; 1982 Jul; 2(7):895-906. PubMed ID: 6124583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic and pharmacological profiles of the in vitro binding of the potent dopamine agonist [3H]N,N-dipropyl-5,6-dihydroxy-2-aminotetralin to rat striatal membranes.
    Mulder TB; Grol CJ; Dijkstra D; Horn AS
    Eur J Pharmacol; 1985 May; 112(1):73-9. PubMed ID: 4018139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively.
    Urwyler S; Markstein R
    J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective storage in vivo of 5,6-ADTN in dopamine-rich areas of the rat brain.
    Westerink BH; Dijkstra D; Feenstra MG; Horn AS; Rollema H
    Eur J Pharmacol; 1980 Jun; 64(2-3):115-21. PubMed ID: 7398758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium ion modulates D2 receptor characteristics of dopamine agonist and antagonist binding sites in striatum and retina.
    Makman MH; Dvorkin B; Klein PN
    Proc Natl Acad Sci U S A; 1982 Jul; 79(13):4212-6. PubMed ID: 6213964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo dopamine (DA) receptor binding and behavioural effects of the putative DA autoreceptor antagonists (+)-AJ 76 and (+)-UH 232 in rats with a unilateral nigral 6-OH-DA lesion.
    Hajos M; Hjorth S; Svensson K; Carlsson A
    Exp Brain Res; 1988; 70(3):577-84. PubMed ID: 3133239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic D-amphetamine and phencyclidine: effects on dopamine agonist and antagonist binding sites in the extrapyramidal and mesolimbic systems.
    Robertson HA
    Brain Res; 1983 May; 267(1):179-82. PubMed ID: 6860944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3H] 2-Amino-6,7-dihydroxy 1,2,3,4-tetrahydronapthalene (ADTN): a potential specific dopamine receptor ligand.
    Clement-Cormier Y; Abel M
    Res Commun Chem Pathol Pharmacol; 1978 Oct; 22(1):15-25. PubMed ID: 725314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prodrug of ADTN: selectivity of dopaminergic action and brain levels of ADTN.
    Horn AS; Kelly P; Westerink BH; Dijkstra D
    Eur J Pharmacol; 1979 Nov; 60(1):95-9. PubMed ID: 574829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for loss of brain [3H]spiroperidil and [3H]ADTN binding sites in rabbit brain with aging.
    Thal LJ; Horowitz SG; Dvorkin B; Makman MH
    Brain Res; 1980 Jun; 192(1):185-94. PubMed ID: 7378779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of [3H]ADTN to rat striatal membranes.
    Templeton WW; Woodruff GN
    Biochem Pharmacol; 1982 Apr; 31(8):1629-32. PubMed ID: 6124259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of dopamine release in the denervated striatum.
    Altar CA; Marien MR
    Neurosci Lett; 1989 Jan; 96(3):329-34. PubMed ID: 2497410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential sensitivity of dopamine release and clearance to 6-hydroxydopamine lesioning in rat striatum.
    Wang Y; Tang FI; Chiou AL; Wang JY
    Life Sci; 1996; 59(21):1783-92. PubMed ID: 8937505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.